4-(4-acetyl-3-hydroxy-2-propylphenoxy)butanoic acid | 92518-38-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(4-acetyl-3-hydroxy-2-propylphenoxy)butanoic acid
• 英文别名: 4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyric acid
• CAS: 92518-38-2
• 化学式: C₁₅H₂₀O₅
• 分子量: 280.321
• InChiKey: TZJQUAPAYQHQLO-UHFFFAOYSA-N

物化性质

• 熔点：
  138-139 °C
• 沸点：
  498.4±45.0 °C(Predicted)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-butylpyridin-3-amine 、 4-(4-acetyl-3-hydroxy-2-propylphenoxy)butanoic acid 生成 4-(4-acetyl-3-hydroxy-2-propylphenoxy)-N-[4-(3-pyridinyl)butyl]butanamide
  参考文献：
  名称：

  Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids

  摘要：

  该发明涉及以下式的化合物：##STR1## 其中R为氢或较低的烷基，Y为亚烷基；Z为亚烷基，##STR2## 这里的星号表示与取代的乙酰苯酮的结合；R.sub.2为氢或较低的烷氧基；n为1至3的整数；A为##STR3## HET为含氮的5-或6-成员杂环基团，以及它们的酸盐。该发明的式I化合物对于治疗过敏症状，如哮喘和心血管疾病，如心绞痛和心律失常，具有用处。

  公开号：

  US04672066A1
• 作为产物：
  描述：

  2,4-二羟基-3-丙基苯乙酮 在 三乙基硅烷 、 甲酸 、 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 66.0h， 生成 4-(4-acetyl-3-hydroxy-2-propylphenoxy)butanoic acid
  参考文献：
  名称：

  Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives

  摘要：

  A series of derivatives of 2,4-dihydroxy-3-propylacetophenone(1) were prepared and examined for their ability to block leukotriene D4 (LTD4) induced contraction of guinea pig ileum. Straight-chain carboxylic acids where the carboxyl group was separated from the acetophenone moiety by varying numbers of methylenes were evaluated, and maximum activity was obtained with the pentamethylene acid (6). Examination of ring substitution showed that the 2-propyl-3-hydroxy-4-acetyl substitution pattern was required for maximum LTD4 antagonist activity. Additional chain terminal groups were examined, and the acidic 5-tetrazolyl group separated from the acetophenone moiety by four to seven methylenes (26, 23, 27, 28) gave excellent in vitro and in vivo activities. Compound 26 (LY171883) had the best balance of in vitro and in vivo activity. It lacked bronchospastic activity at the doses administered and has been chosen for clinical evaluation.

  DOI：

  10.1021/jm00387a018

文献信息

• Substituted 4-acetyl-3-hydroxyphenoxy alkanoic acids
  申请人：Hoffmann-La Roche Inc.

  公开号：US04628115A1

  公开（公告）日：1986-12-09

  The invention relates to compounds of the formula ##STR1## wherein R is hydrogen or lower alkyl, Z is alkylene of 1 to 10 carbon atoms, --(C*H.sub.2).sub.3 --C.tbd.C--, --C*H.sub.2 --C.tbd.C--(CH.sub.2).sub.3 --, and --(CH.sub.2).sub.2 O].sub.n (CH.sub.2).sub.2 -- wherein n is an integer of 1 to 3, the carbon atom marked with an asterisk is linked to the phenoxy moiety, and salts thereof with pharmaceutically acceptable bases. The compounds of formula I are antagonists of slow reacting substance of anaphylaxis (SRS-A; leukotrienes C.sub.4, D.sub.4 and E.sub.4), which renders them useful as agents for the treatment of allergic conditions.

  该发明涉及以下式的化合物##STR1##其中R是氢或较低的烷基，Z是1至10个碳原子的烷基，--(C*H.sub.2).sub.3 --C.tbd.C--, --C*H.sub.2 --C.tbd.C--(CH.sub.2).sub.3 --，以及--(CH.sub.2).sub.2 O].sub.n (CH.sub.2).sub.2 --其中n是1至3的整数，带有星号标记的碳原子与苯氧基团连接，并且其与药学上可接受的碱盐。式I的化合物是过敏反应缓慢反应物（SRS-A;白三烯C.sub.4，D.sub.4和E.sub.4）的拮抗剂，使它们在过敏症状治疗剂方面有用。
• Heterocyclic compounds, their production, and medicaments containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0181779A1

  公开（公告）日：1986-05-21

  Compounds of formula I and salts thereof are useful for the treatment and prophylaxis of allergic diseases. Production and use of the compounds is described.

  式 I 的化合物 及其盐类可用于治疗和预防过敏性疾病。本文介绍了这些化合物的生产和使用。
• Phenoxyacetic acid compounds and medical preparations containing them
  申请人：TERUMO KABUSHIKI KAISHA

  公开号：EP0562796A1

  公开（公告）日：1993-09-29

  Disclosed are phenoxyacetic acid compounds of formula (I): where X is a hydrogen atom, a lower alkyl group or a halogen atom; R1 is a carboxyl group or a lower alkoxycarbonyl group; Y is an oxygen atom, or n is an integer of from 0 to 5; Z is or R2 is a hydrogen atom or a lower alkyl group; and m is 0 or 1. The compounds and their physiologically acceptable salts are used as thromboxane A2 antagonistic agents, leukotriene antagonistic agents and/or anti-allergic agents.

  所公开的是式 (I) 的苯氧乙酸化合物： 其中 X 是氢原子、低级烷基或卤素原子； R1 是羧基或低级烷氧羰基； Y 是氧原子、 或 n 是 0 至 5 的整数； Z 是 或 R2 是氢原子或低级烷基；以及 m 为 0 或 1。 这些化合物及其生理上可接受的盐类可用作血栓素 A2 拮抗剂、白三烯拮抗剂和/或抗过敏剂。
• Leukotriene antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0108592B1

  公开（公告）日：1987-09-30
• MURASE, KIYOSHI;MASE, TOSHIYASU;HARA, HIROMU;TOMIOKA, KENICHI
  作者：MURASE, KIYOSHI、MASE, TOSHIYASU、HARA, HIROMU、TOMIOKA, KENICHI

  DOI：——

  日期：——